Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InsigHHT: Phase 1/2 Study of ALN-6400 in Healthy Volunteers and Patients with Hereditary Hemorrhagic Telangiectasia
2025-522510-23-00Phase 2Authorised
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Nov 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in hereditary hemorrhagic telangiectasia (HHT) comparing ALN-6400 with Placebo (2 arms). Primary endpoint: Frequency of adverse events. Planned start Nov 2025; status: authorised.
02
Drugs
ALN-6400
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on 2025-522510-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522510-23-00.